Isabel Losantos, senior consultant - Design Assurance, at Cambridge Consultants and Joe Corrigan, head of Medical Technology examine the potential AI represents in life sciences and the regulatory changes it brings.
Vanessa Fachada Oliveira, pharmacovigilance manager & EU QPPV at Arriello, highlights key areas of focus for marketing authorisation holders to achieve an effective audit of their pharmacovigilance systems.
David Knight, partner and Joshua Marshall, senior associate at Fieldfisher discuss the implications the Covid-19 Technology Access Pool is having on innovation in pharma.
Maurits Lugard, Dr. Dorothee Schramm, and Anna-Shari Melin from law firm Sidley & Austin explain how pharmaceutical companies with products on the EU market can address product shortages and supply chain issues in the current Covid-19 crisis.
As the Covid-19 pandemic continues, pharmaceutical companies are taking generous steps and removing intellectual property rights for many key drugs which could help fight the virus.
Anna Lukyanova, COO of life sciences compliance proivider Arriello, explains why tight project management is essential for success in pharma outsourcing.
Marie Manley, partner at law firm Sidley Austin, and associates, look at how UK and EU life sciences are responding to the regulatory requirements presented by Covid-19.
